First Time Loading...

Reata Pharmaceuticals Inc
NASDAQ:RETA

Watchlist Manager
Reata Pharmaceuticals Inc Logo
Reata Pharmaceuticals Inc
NASDAQ:RETA
Watchlist
Price: 172.36 USD Market Closed
Updated: Apr 18, 2024

Intrinsic Value

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. [ Read More ]

The intrinsic value of one RETA stock under the Base Case scenario is 73.26 USD. Compared to the current market price of 172.36 USD, Reata Pharmaceuticals Inc is Overvalued by 57%.

Key Points:
RETA Intrinsic Value
Base Case
73.26 USD
Overvaluation 57%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Reata Pharmaceuticals Inc

Backtest Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling RETA stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

Beta
Ask me anything about
Reata Pharmaceuticals Inc

Provide an overview of the primary business activities
of Reata Pharmaceuticals Inc.

What unique competitive advantages
does Reata Pharmaceuticals Inc hold over its rivals?

What risks and challenges
does Reata Pharmaceuticals Inc face in the near future?

Has there been any significant insider trading activity
in Reata Pharmaceuticals Inc recently?

Summarize the latest earnings call
of Reata Pharmaceuticals Inc.

Is it considered overvalued or undervalued
based on the latest financial data?

Show all valuation multiples
for Reata Pharmaceuticals Inc.

Provide P/S
for Reata Pharmaceuticals Inc.

Provide P/E
for Reata Pharmaceuticals Inc.

Provide P/OCF
for Reata Pharmaceuticals Inc.

Provide P/FCFE
for Reata Pharmaceuticals Inc.

Provide P/B
for Reata Pharmaceuticals Inc.

Provide EV/S
for Reata Pharmaceuticals Inc.

Provide EV/GP
for Reata Pharmaceuticals Inc.

Provide EV/EBITDA
for Reata Pharmaceuticals Inc.

Provide EV/EBIT
for Reata Pharmaceuticals Inc.

Provide EV/OCF
for Reata Pharmaceuticals Inc.

Provide EV/FCFF
for Reata Pharmaceuticals Inc.

Provide EV/IC
for Reata Pharmaceuticals Inc.

Show me price targets
for Reata Pharmaceuticals Inc made by professional analysts.

What are the Revenue projections
for Reata Pharmaceuticals Inc?

How accurate were the past Revenue estimates
for Reata Pharmaceuticals Inc?

What are the Net Income projections
for Reata Pharmaceuticals Inc?

How accurate were the past Net Income estimates
for Reata Pharmaceuticals Inc?

What are the EPS projections
for Reata Pharmaceuticals Inc?

How accurate were the past EPS estimates
for Reata Pharmaceuticals Inc?

What are the EBIT projections
for Reata Pharmaceuticals Inc?

How accurate were the past EBIT estimates
for Reata Pharmaceuticals Inc?

Compare the revenue forecasts
for Reata Pharmaceuticals Inc with those of its competitors based on recent analyst estimates.

Compare the intrinsic valuations
of Reata Pharmaceuticals Inc and its key competitors using the latest financial data.

Compare historical revenue growth rates
of Reata Pharmaceuticals Inc against its competitors.

Analyze the profit margins
(gross, operating, and net) of Reata Pharmaceuticals Inc compared to its peers.

Compare the P/E ratios
of Reata Pharmaceuticals Inc against its peers.

Discuss the investment returns and shareholder value creation
comparing Reata Pharmaceuticals Inc with its peers.

Analyze the financial leverage
of Reata Pharmaceuticals Inc compared to its main competitors.

Show all profitability ratios
for Reata Pharmaceuticals Inc.

Provide ROE
for Reata Pharmaceuticals Inc.

Provide ROA
for Reata Pharmaceuticals Inc.

Provide ROIC
for Reata Pharmaceuticals Inc.

Provide ROCE
for Reata Pharmaceuticals Inc.

Provide Gross Margin
for Reata Pharmaceuticals Inc.

Provide Operating Margin
for Reata Pharmaceuticals Inc.

Provide Net Margin
for Reata Pharmaceuticals Inc.

Provide FCF Margin
for Reata Pharmaceuticals Inc.

Show all solvency ratios
for Reata Pharmaceuticals Inc.

Provide D/E Ratio
for Reata Pharmaceuticals Inc.

Provide D/A Ratio
for Reata Pharmaceuticals Inc.

Provide Interest Coverage Ratio
for Reata Pharmaceuticals Inc.

Provide Altman Z-Score Ratio
for Reata Pharmaceuticals Inc.

Provide Quick Ratio
for Reata Pharmaceuticals Inc.

Provide Current Ratio
for Reata Pharmaceuticals Inc.

Provide Cash Ratio
for Reata Pharmaceuticals Inc.

What is the historical Revenue growth
over the last 5 years for Reata Pharmaceuticals Inc?

What is the historical Net Income growth
over the last 5 years for Reata Pharmaceuticals Inc?

What is the current Free Cash Flow
of Reata Pharmaceuticals Inc?

Financials

Balance Sheet Decomposition
Reata Pharmaceuticals Inc

Current Assets 401.8m
Cash & Short-Term Investments 330.2m
Receivables 22.7m
Other Current Assets 49m
Non-Current Assets 100.7m
PP&E 89.9m
Other Non-Current Assets 10.8m
Current Liabilities 125.1m
Accounts Payable 19.9m
Accrued Liabilities 27.6m
Other Current Liabilities 77.6m
Non-Current Liabilities 290.2m
Long-Term Debt 73.1m
Other Non-Current Liabilities 217.1m
Efficiency

Earnings Waterfall
Reata Pharmaceuticals Inc

Revenue
23.5m USD
Cost of Revenue
-1.6m USD
Gross Profit
21.9m USD
Operating Expenses
-363.6m USD
Operating Income
-341.7m USD
Other Expenses
254m USD
Net Income
-87.6m USD

Free Cash Flow Analysis
Reata Pharmaceuticals Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

RETA Profitability Score
Profitability Due Diligence

Reata Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

Exceptional 3-Year Average ROE
Exceptional Revenue Growth Forecast
Exceptional 1-Year Revenue Growth
ROIC is Increasing
41/100
Profitability
Score

Reata Pharmaceuticals Inc's profitability score is 41/100. The higher the profitability score, the more profitable the company is.

RETA Solvency Score
Solvency Due Diligence

Reata Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Negative Net Debt
Short-Term Solvency
Low D/E
Long-Term Solvency
42/100
Solvency
Score

Reata Pharmaceuticals Inc's solvency score is 42/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

RETA Price Targets Summary
Reata Pharmaceuticals Inc

Wall Street analysts forecast RETA stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for RETA is 172.4 USD .

Lowest
Price Target
Not Available
Average
Price Target
172.4 USD
0% Upside
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Ownership

RETA Insider Trading
Buy and sell transactions by insiders

Cumulative Transactions Amount
Period Sold Bought Net
3 Months
6 Months
9 Months
12 Months
Why is insider trading important?

Shareholder Return

RETA Price
Reata Pharmaceuticals Inc

1M 1M
-
6M 6M
-
1Y 1Y
+74%
3Y 3Y
+89%
5Y 5Y
+120%
10Y 10Y
+1 219%
Annual Price Range
172.36
52w Low
79.22
52w High
172.36
Price Metrics
Average Annual Return 14.98%
Standard Deviation of Annual Returns 130.2%
Max Drawdown -92%
Shares Statistics
Market Capitalization 6.5B USD
Shares Outstanding 37 553 034
Percentage of Shares Shorted 8.14%

RETA Return Decomposition
Main factors of price return

What is price return decomposition?

RETA News

Other Videos

Last Important Events
Reata Pharmaceuticals Inc

Significant happenings or occurrences that are of interest to investors. These could be company-specific developments or market-wide shifts.

All
Positive
Negative

Sentiment Analysis
Reata Pharmaceuticals Inc

Today
Last 7 Days 7D
Last 30 Days 30D
Last 90 Days 90D

Company Profile

Reata Pharmaceuticals Inc Logo
Reata Pharmaceuticals Inc

Country

United States of America

Industry

Pharmaceuticals

Market Cap

6.5B USD

Dividend Yield

0%

Description

Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. The company is headquartered in Plano, Texas and currently employs 346 full-time employees. The company went IPO on 2016-05-26. The firm is also focused on providing small-molecule therapeutics with mechanisms of action for the treatment of severe, life-threatening diseases with therapies. Its lead programs are omaveloxolone in a neurological disease called Friedreich’s ataxia (FA) and bardoxolone methyl (bardoxolone) in rare forms of chronic kidney disease (CKD). The Company’s lead product candidates activate the transcription factor Nrf2 to normalize mitochondrial function, restore redox balance, and resolve inflammation. The company is also developing RTA 901, the lead product candidate from its Hsp90 modulator program, in neurological indications. Omaveloxolone and bardoxolone are Nuclear factor-erythroid factor 2-related factor 2 (Nrf2) activators that selectively bind to Keap1, a protein that governs the activity of Nrf2 in response to cellular stress.

Contact

TEXAS
Plano
5320 Legacy Dr
+19728652219.0
https://www.reatapharma.com/

IPO

2016-05-26

Employees

346

Officers

Chairman & CEO
Mr. J. Warren Huff
COO, CFO & Pres
Mr. Manmeet Singh Soni
Exec. VP & Chief Legal Officer
Mr. Michael D. Wortley
Exec. VP & Chief Innovation Officer
Dr. Colin J. Meyer M.D.
Exec. VP & Chief Commercial Officer
Ms. Dawn Carter Bir
VP & Chief Accounting Officer
Mr. Bhaskar Anand
Show More
Sr. VP & Chief Scientific Officer
Dr. W. Christian Wigley Ph.D.
VP & Chief Healthcare Compliance Officer
Mr. Dakota Gallivan
Sr. VP & Chief HR Officer
Mr. Steve Harman
Consultant
Ms. Elaine Castellanos
Show Less

See Also

Discover More
What is the Intrinsic Value of one RETA stock?

The intrinsic value of one RETA stock under the Base Case scenario is 73.26 USD.

Is RETA stock undervalued or overvalued?

Compared to the current market price of 172.36 USD, Reata Pharmaceuticals Inc is Overvalued by 57%.